4583 Chiome Bioscience Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4583

TSE Growth

Chiome Bioscience Inc.

245

JPY

+10

(+4.26%)

Dec 23, 2:56 pm JST

1.56

USD

Dec 23, 12:56 am EST

Result

ー

PTS

outside of trading hours

244.9

Dec 23, 2:55 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2020	480	-1,283	-1,291	-1,293	-36.1	0	Feb 9, 2021	J-GAAP
Dec, 2021	712	-1,334	-1,329	-1,479	-36.7	0	Feb 14, 2022	J-GAAP
Dec, 2022	630	-1,258	-1,243	-1,242	-28.3	0	Feb 14, 2023	J-GAAP
Dec, 2023	682	-1,205	-1,217	-1,220	-24.6	0	Feb 13, 2024	J-GAAP
Dec, 2024 Guidance	600	ー	ー	ー	－	0	Nov 12, 2024	J-GAAP
YoY	-12.0%	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2019	Feb 14, 2019	ー	ー	ー	ー	0	J-GAAP
- - - - Results	Feb 14, 2020	447	-1,401	-1,410	-1,403	0	J-GAAP
Dec, 2020	Feb 14, 2020	Available in future release
Results	Feb 9, 2021
Dec, 2021	Feb 9, 2021
Results	Feb 14, 2022
Dec, 2022	Feb 14, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
Results	Feb 13, 2024
Dec, 2024	Feb 13, 2024	720	ー	ー	ー	0	J-GAAP
- - -	Nov 12, 2024	600	ー	ー	ー	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2007	13	－	Available in future release
Mar, 2008	34	+161.5
Mar, 2009	161	+373.5
Mar, 2010	380	+136.0
Mar, 2011	463	+21.8
Mar, 2012	633	+36.7
Mar, 2013	324	-48.8
Mar, 2014	434	+34.0
Dec, 2014 Changed	277	－
Dec, 2015	280	+1.1
Dec, 2016	252	-10.0
Dec, 2017	259	+2.8
Dec, 2018	212	-18.1
Dec, 2019	447	+110.8
Dec, 2020	480	+7.4
Dec, 2021	712	+48.3
Dec, 2022	630	-11.5
Dec, 2023	682	+8.3
Dec, 2024 Guidance	600	-12.0	ー	+100.0	ー	+100.0	－	+100.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2022	630	-1,258	-200	-68.35	-54.55	0.28	-28.3
Dec, 2023	682	-1,205	-177	-83.68	-61.52	0.34	-24.6
Dec, 2024 Guidance	600	ー	ー	ー	ー	0.35	－

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	712	-7	-42	-44	-3.0
Fiscal Year	Dec, 2021	Mar, 2012	Mar, 2012	Mar, 2012	Mar, 2012

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2021	328	-919	-920	-1,071	-26.6	0	Feb 14, 2022	J-GAAP
Jul - Dec, 2022	352	-479	-475	-471	-10.7	0	Feb 14, 2023	J-GAAP
Jul - Dec, 2023	324	-546	-555	-557	-11.2	0	Feb 13, 2024	J-GAAP
Jul - Dec, 2024 Guidance	337	ー	ー	ー	－	0	Nov 12, 2024	J-GAAP
YoY	+4.0%	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2021	-1,334	-1,166	-1,131	-35	271	1,790	76.53	J-GAAP
Dec, 2022	-1,258	-1,191	-1,191	0	1,127	1,727	77.97	J-GAAP
Dec, 2023	-1,205	-1,069	-1,069	0	667	1,325	75.67	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2022	433	-1,039	-1,029	-1,027	-23.9	ー	Nov 14, 2022	J-GAAP
Jan - Sep, 2023	524	-905	-916	-918	-18.8	ー	Nov 14, 2023	J-GAAP
Jan - Sep, 2024	422	-920	-914	-915	-16.3	ー	Nov 12, 2024	J-GAAP
YoY	-19.5%	-1.7%	+0.2%	+0.3%	+13.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	197	-219	-214	-215	-4.9	-111.2	Feb 14, 2023	J-GAAP
Jan - Mar, 2023	169	-225	-227	-227	-4.7	-133.1	May 11, 2023	J-GAAP
Apr - Jun, 2023	189	-434	-435	-436	-9.0	-229.6	Aug 9, 2023	J-GAAP
Jul - Sep, 2023	166	-246	-254	-255	-5.2	-148.2	Nov 14, 2023	J-GAAP
Oct - Dec, 2023	158	-300	-301	-302	-6.1	-189.9	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	129	-322	-303	-304	-5.6	-249.6	May 14, 2024	J-GAAP
Apr - Jun, 2024	134	-259	-260	-259	-4.7	-193.3	Aug 13, 2024	J-GAAP
Jul - Sep, 2024	159	-339	-351	-352	-6.3	-213.2	Nov 12, 2024	J-GAAP
YoY	-4.2%	-37.8%	-38.2%	-38.0%	-19.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	165	+135.7	Available in future release
Jan - Mar, 2020	90	+42.9
Apr - Jun, 2020	83	+7.8
Jul - Sep, 2020	139	-2.1
Oct - Dec, 2020	168	+1.8
Jan - Mar, 2021	246	+173.3
Apr - Jun, 2021	138	+66.3
Jul - Sep, 2021	157	+12.9
Oct - Dec, 2021	171	+1.8
Jan - Mar, 2022	128	-48.0
Apr - Jun, 2022	150	+8.7
Jul - Sep, 2022	155	-1.3
Oct - Dec, 2022	197	+15.2
Jan - Mar, 2023	169	+32.0
Apr - Jun, 2023	189	+26.0
Jul - Sep, 2023	166	+7.1
Oct - Dec, 2023	158	-19.8
Jan - Mar, 2024	129	-23.7
Apr - Jun, 2024	134	-29.1
Jul - Sep, 2024	159	-4.2	-339	-37.8	-351	-38.2	-6.3	-21.2

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	246	35	32	32	2.2
Fiscal Year	Mar, 2021	Mar, 2012	Mar, 2012	Mar, 2012	Mar, 2012

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2021	45.55	79.4	2,339	1,857	-2,773	0.10	Feb 14, 2022	J-GAAP
Dec, 2022	36.70	80.2	2,215	1,777	-4,016	0.10	Feb 14, 2023	J-GAAP
Dec, 2023	21.66	65.0	1,751	1,139	-5,236	0.26	Feb 13, 2024	J-GAAP
Jan - Sep, 2024	ー	70.9	1,693	1,201	-915	0.25	Nov 12, 2024	J-GAAP

Chiome Bioscience Inc.(4583) Financial Results